Dynavax Technologies Corporation (NASDAQ: DVAX) announced results from HBV-23, a pivotal Phase 3 trial that provides head-to-head safety and immunogenicity ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE